Print Page

Letters to Healthcare Providers
 
Cholinesterase Inhibitors (donepezil-, rivastigmine- and galantamine-containing products) - Assessing the potential risk of QT interval prolongation and torsade de pointes (Letter to Healthcare Professionals)
 
 
 
Attachment:
  1. Cholinesterase Inhibitors (donepezil-, rivastigmine- and galantamine-containing products) - Assessing the potential risk of QT interval prolongation and torsade de pointes  
Related Information:
Singapore: QT prolongation and Torsades de Pointes with donepezil Posted 2022-08-31
Canada: Summary Safety Review: Cholinesterase inhibitors (donepezil-, rivastigmi... Posted 2022-07-20
Donepezil and cardiac conduction disorders (Letter to Healthcare Professionals) Posted 2022-03-01
Australia: Donepezil and cardiac conduction disorders Posted 2022-03-01
 
back